Alzheimer's Disease
New England Journal of MedicinePublished 30 June 2004
Jeffrey L. Cummings
Citations1,117
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
Abstract
The prevalence of Alzheimer's disease is predicted to reach 13.2 million cases in the United States. This article considers current therapeutic approaches for Alzheimer's disease. Optimal management requires accurate diagnosis, which is increasingly based on an understanding of pathophysiology. Neuroprotective strategies, cholinesterase inhibitors, psychopharmacologic agents that may reduce behavioral disturbances, and newer agents such as memantine are discussed.
Keywords
Medicine
NeurologyClinical diagnosis of Alzheimer's disease
27,993 Citations1984Guy M. McKhann, David A. Drachman +4 more
The criteria proposed are intended to serve as a guide for the diagnosis of probable, possible, and definite Alzheimer's disease; these criteria will be revised as more definitive information becomes available.
ScienceThe Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
13,830 Citations2002John Hardy, Dennis J. Selkoe
It has been more than 10 years since it was first proposed that the neurodegeneration in Alzheimer's disease (AD) may be caused by deposition of amyloid β-peptide in plaques in brain tissue, and accumulation of Aβ in the brain is the primary influence driving AD pathogenesis.
ScienceCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
4,213 Citations1996Karen Hsiao, Paul F. Chapman +6 more
Transgenic mice overexpressing the 695-amino acid isoform of human Alzheimer β-amyloid (Aβ) precursor protein containing a Lys670 → Asn, Met671 → Leu mutation had normal learning and memory but showed impairment by 9 to 10 months of age.
American Journal of PsychiatryA new rating scale for Alzheimer's disease
4,123 Citations1984Wilma G. Rosen, Richard C. Mohs +1 more
A new rating instrument, the Alzheimer's Disease Assessment Scale, was designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic of persons with Alzheimer's disease.
NatureImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
3,151 Citations1999Dale Schenk, Robin Barbour +23 more
It is reported that immunization of the young animals essentially prevented the development of β-amyloid-plaque formation, neuritic dystrophy and astrogliosis, and treatment of the older animals markedly reduced the extent and progression of these AD-like neuropathologies.
New England Journal of MedicineA Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
2,371 Citations1997Mary Sano, Christopher Ernesto +10 more
In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.
Archives of NeurologyAlzheimer Disease in the US Population
2,166 Citations2003Liesi E. Hebert, Paul A. Scherr +3 more
The number of persons with AD in the US population will continue to increase unless new discoveries facilitate prevention of the disease, according to current and future estimates of prevalence of clinically diagnosed AD.
JAMAEstrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women
2,149 Citations2003Sally A. Shumaker, Claudine Legault +12 more
New England Journal of MedicineMemantine in Moderate-to-Severe Alzheimer's Disease
2,019 Citations2003Barry Reisberg, Rachelle S. Doody +4 more
Antiglutamatergic treatment reduced clinical deterioration in moderate-to-severe Alzheimer's disease, a phase associated with distress for patients and burden on caregivers, for which other treatments are not available.
The GerontologistPsychiatric and Physical Morbidity Effects of Dementia Caregiving: Prevalence, Correlates, and Causes
1,785 Citations1995R. Schulz, Alison T. O'Brien +2 more
Across studies, psychiatric morbidity in caregivers was linked to patient problem behaviors, income, self-rated health, perceived stress, and life satisfaction, and physical morbidity was associated with patient Problem behaviors and cognitive impairment, and with caregiver depression, anxiety, and perceived social support.
NeurologyPractice parameter: Management of dementia (an evidence-based review) [RETIRED]
1,722 Citations2001Rachelle S. Doody, J E Stevens +9 more
NeurologyA 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
1,606 Citations1998Samantha Rogers, Martin R. Farlow +4 more
The data indicate that donepezil is a well-tolerated drug that improves cognition and global function in patients with mild to moderate AD.
NeurologyPractice parameter: Diagnosis of dementia (an evidence-based review)
1,391 Citations2001David S. Knopman, Steven T. DeKosky +7 more
JAMAMemantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil
1,375 Citations2004Pierre N. Tariot, Martin R. Farlow +5 more
In patients with moderate to severe AD receiving stable doses of donepezil, memantine resulted in significantly better outcomes than placebo on measures of cognition, activities of daily living, global outcome, and behavior and was well tolerated.
NeurologySubacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
1,330 Citations2003J. M. Orgogozo, S. Gilman +12 more
Postvaccination meningoencephalitis occurred without clear relation to serum anti-Aβ42 antibody titers and potential mechanisms such as T-cell and microglial activation may be responsible and are under consideration to develop a safer anti- Aβ immunotherapy for AD.
Alzheimer Disease & Associated DisordersAn Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
1,163 Citations1997Douglas Galasko, David A. Bennett +5 more
NeurologyThe spectrum of behavioral changes in Alzheimer's disease
1,109 Citations1996Michael S. Mega, Jeffrey L. Cummings +2 more
Agitation, dysphoria, apathy, and aberrant motor behavior were significantly correlated with cognitive impairment in patients with Alzheimer's disease compared with normal age-matched control subjects.
JAMADietary Intake of Antioxidants and Risk of Alzheimer Disease
1,060 Citations2002Marianne J. Engelhart
High dietary intake of vitamin C and vitamin E may lower the risk of Alzheimer disease.
PubMedEstrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study.
988 Citations2000Ruth A. Mulnard, Carl W. Cotman +11 more
Estrogen replacement therapy for 1 year did not slow disease progression nor did it improve global, cognitive, or functional outcomes in women with mild to moderate AD, and the study does not support the role of estrogen for the treatment of this disease.
Archives of NeurologyMetal-Protein Attenuation With Iodochlorhydroxyquin (Clioquinol) Targeting Aβ Amyloid Deposition and Toxicity in Alzheimer Disease
972 Citations2003Craig Ritchie, Ashley I. Bush +17 more
This pilot phase 2 study supports further investigation of this novel treatment strategy using a metal-protein-attenuating compound, and the effect of treatment was significant in the more severely affected group.
PubMedEffects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
968 Citations2003Paul Aisen, Kimberly Schafer +8 more
The results of this study indicate that rofecoxib or low-dose naproxen does not slow cognitive decline in patients with mild-to-moderate AD.
Journal of the American Geriatrics SocietyMeta‐Analysis of Psychosocial Interventions for Caregivers of People with Dementia
955 Citations2003Henry Brodaty, Alisa Green +1 more
To review published reports of interventions for caregivers of persons with dementia, excluding respite care, and provide recommendations to clinicians, is reviewed.
JAMAPositron Emission Tomography in Evaluation of Dementia
949 Citations2001Daniel Silverman, Gary W. Small +22 more
In patients presenting with cognitive symptoms of dementia, regional brain metabolism was a sensitive indicator of AD and of neurodegenerative disease in general and a negative PET scan indicated that pathologic progression of cognitive impairment during the mean 3-year follow-up was unlikely to occur.
NeurologyGalantamine in AD
871 Citations2000Murray A. Raskind, Elaine R. Peskind +3 more
Galantamine is effective and safe in AD and significantly improved cognition and global function at 6 months, and cognitive and daily function were maintained for 12 months with the 24 mg/d dose.
NeuropharmacologyMemantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data
868 Citations1999Chris G. Parsons, Wojciech Danysz +1 more
Preclinical data on memantine is summarized to provide evidence that it is indeed possible to develop clinically well tolerated NMDA receptor antagonists, a fact reflected in the recent interest of several pharmaceutical companies in developing compounds with similar properties to memantine.
NeuronAntibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease
781 Citations2003Christoph Höck, Uwe Konietzko +15 more
It is established that antibodies against beta-amyloid plaques can slow cognitive decline in patients with Alzheimer's disease.
The Journal of Clinical PsychiatryComparison of Risperidone and Placebo for Psychosis and Behavioral Disturbances Associated With Dementia
746 Citations1999Ira R. Katz, Dilip V. Jeste +5 more
Results show that 1 mg/day of risperidone is an appropriate dose for most elderly patients with dementia, and significantly improved symptoms of psychosis and aggressive behavior in patients with severe dementia.
NeurologyA 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
728 Citations2001Bengt Winblad, Knut Engedal +9 more
As the first 1-year, multinational, double-blinded, placebo-controlled study of a cholinesterase inhibitor in AD, data support donepezil as a well tolerated and effective long-term treatment for patients with AD, with benefits over placebo on global assessment, cognition, and ADL.
PubMedReduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study.
719 Citations2004Peter P. Zandi, James C. Anthony +7 more
Use of vitamin E and vitamin C supplements in combination is associated with reduced prevalence and incidence of AD, and antioxidant supplements merit further study as agents for the primary prevention of AD.
Neurobiology of AgingEvidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death1
715 Citations2002D ALLANBUTTERFIELD, Alessandra Castegna +2 more
Results are consistent with the notion of a coupling of the oxidative environment in AD brain and increased risk of developing this disorder and strongly support a causative role of Abeta(1-42)-induced oxidative stress in AD neurodegeneration.
Alzheimer Disease & Associated DisordersValidity and Reliability of the Alzheimerʼs Disease Cooperative Study-Clinical Global Impression of Change
652 Citations1997Lara Schneider, Jason T. Olin +8 more
The ADCS-CGIC ratings at 12 months were significantly associated with change on four severity scales, and change ratings were sensitive to dementia severity.
NeurologyA randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
618 Citations1999Peter Paul De Deyn, Kiran Rabheru +5 more
Low-dose risperidone (mean 1.1 mg/d) was well tolerated and associated with reductions in the severity and frequency of behavioral symptoms, particularly aggression, in elderly patients with dementia.
Archives of General PsychiatryOlanzapine Treatment of Psychotic and Behavioral Symptoms in Patients With Alzheimer Disease in Nursing Care Facilities
600 Citations2000J. Street
Low-dose olanzapine (5 and 10 mg/d) was significantly superior to placebo and well tolerated in treating agitation/aggression and psychosis in this population of patients with AD.
American Journal of Geriatric PsychiatryNonpharmacologic Interventions for Inappropriate Behaviors in Dementia: A Review, Summary, and Critique
586 Citations2001Jiska Cohen‐Mansfield
A literature search yielded 83 nonpharmacological intervention studies, which utilized the following categories of interventions: sensory, social contact, behavior therapy, staff training, structured activities, environmental interventions, medical/nursing care interventions, and combination therapies.
Archives of NeurologyThe Efficacy of Ginkgo biloba on Cognitive Function in Alzheimer Disease
584 Citations1998Barry Oken, Daniel Storzbach +1 more
There is a small but significant effect of 3- to 6-month treatment with 120 to 240 mg of G. biloba extract on objective measures of cognitive function in patients with Alzheimer disease.
NeurologyCerebrospinal fluid and plasma insulin levels in Alzheimer's disease
560 Citations1998Suzanne Craft, Elaine R. Peskind +4 more
Patients with Alzheimer's disease have elevations of fasting plasma insulin that are hypothesized to be associated with disrupted brain insulin metabolism, and there are metabolic differences among apolipoprotein E genotypes.
NeurologyEstrogen for Alzheimer’s disease in women
551 Citations2000Victor W. Henderson, Annlia Paganini‐Hill +8 more
Results suggest that short-term estrogen therapy does not improve symptoms of most women with AD, and these findings do not address possible long-term effects of estrogen in AD, possible interactions between estrogen and other treatment modalities, or putative effects ofosterone in preventing or delaying onset of this disorder.
Annals of Internal MedicineDocumentation and Evaluation of Cognitive Impairment in Elderly Primary Care Patients
526 Citations1995Christopher M. Callahan, Hugh C. Hendrie +1 more
The Journal of Clinical PsychiatryA Randomized Placebo-Controlled Trial of Risperidone for the Treatment of Aggression, Agitation, and Psychosis of Dementia
464 Citations2003Henry Brodaty, David Ames +7 more
Treatment with low-dose risperidone resulted in significant improvement in aggression, agitation, and psychosis associated with dementia.
NeurologyA randomized controlled trial of prednisone in Alzheimer’s disease
452 Citations2000Paul Aisen, Keith L. Davis +10 more
NeuronNeuroplasticity Failure in Alzheimer's Disease
445 Citations1999M.‐Marsel Mesulam
This research examines the role of language impairment in the development of Alzheimer's disease and the role that language impairment plays in the progression of disease.
American Journal of PsychiatryEfficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia
419 Citations1998Pierre N. Tariot, Rosemary Erb +5 more
A 6-week, randomized, multisite, parallel-group study of 51 nursing home patients with agitation and dementia showed significant short-term efficacy of carbamazepine for agitation with generally good safety and tolerability.
NeurologyA double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease
392 Citations1999Simon Scharf, Alastair Mander +3 more
This pilot study, with small treatment numbers, did not demonstrate a significant effect of NSAID treatment in AD, but the trends observed justify further investigations with a larger number of participants.
Journal of the American Geriatrics SocietyA Randomized, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting
370 Citations2001Pierre N. Tariot, Jeffrey L. Cummings +5 more
The safety and efficacy of donepezil in the management of patients with Alzheimer's disease residing in nursing home facilities is evaluated.
Archives of NeurologyOpen-Label, Multicenter, Phase 3 Extension Study of the Safety and Efficacy of Donepezil in Patients With Alzheimer Disease
361 Citations2001Rachelle S. Doody
Donepezil is an effective and safe drug for the long-term symptomatic treatment of mild to moderately severe AD for up to 144 weeks (2.8 years), and sustained treatment may confer some advantages.
Neurobiology of AgingA review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes
320 Citations2002Emanuela Esposito, Domenico Rotilio +4 more
The biochemical mechanisms by which nutritional antioxidants can reduce or block neuronal death occurring in neurodegenerative disorders are reviewed and particular emphasis will be given to the role played by the nuclear transcription factor-kappaB (NF- kappaB) in apoptosis, and in the pathogenesis of neurodegenersative disorders, such as AD, PD, and ALS.
Archives of NeurologyExplicit Memory in Alzheimer's, Huntington's, and Parkinson's Diseases
313 Citations1993B. Pillon, Bernard Deweer +2 more
Clear distinction is made between the true amnesic syndrome of SDAT, compatible with lesions of hippocampus and temporal cortex, and the inefficient planning of memory processes of Huntington's disease and Parkinson's disease, which might result from a striatofrontal dysfunction.
NeuropsychologiaAnalysis of the episodic memory deficit in early Alzheimer's disease: Evidence from the doors and people test
272 Citations1996J Greene, Alan Baddeley +1 more
It was concluded that the episodic memory deficit in DAT is general in nature and primarily reflects impaired learning rather than accelerated forgetting or disrupted retrieval.
European NeuropsychopharmacologyLong-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study
267 Citations2000Samantha Rogers, Rachelle S. Doody +2 more
Data demonstrate that donepezil is a well-tolerated, realistic symptomatic treatment for AD over a period of up to 4.9 years, and there was no evidence of hepatotoxicity.
American Journal of PsychiatryA Randomized, Placebo-Controlled Dose-Comparison Trial of Haloperidol for Psychosis and Disruptive Behaviors in Alzheimer’s Disease
238 Citations1998D. P. Devanand, Karen Marder +7 more
A favorable therapeutic profile for haloperidol in doses of 2-3 mg/day, although a subgroup developed moderate to severe extrapyramidal signs, may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.
The Journals of Gerontology Series AManagement of Verbally Disruptive Behaviors in Nursing Home Residents
235 Citations1997Jiska Cohen‐Mansfield, P. Werner
The effects of the interventions were clinically and statistically significant, indicating the importance of providing stimulating activities and a richer environment to cognitively impaired nursing home residents.
American Journal of PsychiatryRandomized, Placebo-Controlled, Double-Blind Clinical Trial of Sertraline in the Treatment of Depression Complicating Alzheimer’s Disease: Initial Results From the Depression in Alzheimer’s Disease Study
213 Citations2000Constantine G. Lyketsos, Jeannie‐Marie E. Sheppard +6 more
American Journal of Geriatric PsychiatryUse of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations
202 Citations2003Jeffrey L. Cummings
In general, ChE-Is exert modest reproducible effects in patients with mild-to-moderate AD, and drug-placebo differences are evident on global and cognitive measures.
American Journal of Geriatric PsychiatryPlacebo-Controlled Study of Divalproex Sodium for Agitation in Dementia
197 Citations2001Anton P. Porsteinsson, Pierre N. Tariot +8 more
This placebo-controlled study, despite some limitations, suggests possible short-term efficacy, tolerability, and safety of divalproex for agitation in dementia and supports further placebo- controlled studies.
Annals of NeurologyPossible neurotransmitter basis of behavioral changes in alzheimer's disease
196 Citations1988Alan M. Palmer, Gary C. Stratmann +2 more
It is argued that the large loss of indoleamines from the frontal lobe (to 50–63% of control values) is rather unexpected based on other biochemical measurements and may relate to behavioral changes.
Nature Reviews Drug DiscoveryTherapeutic strategies for Alzheimer's disease
190 Citations2002Michael S. Wolfe
The main efforts for developing therapeutics are focused on preventing amyloid-β production, aggregation or downstream neurotoxic events and the progress of these approaches raises the hope that effective agents for the prevention and treatment of Alzheimer's disease will be available in the near future.
PsychosomaticsA Double-Blind, Randomized, Fixed-Dose Trial of Fluoxetine vs. Amitriptyline in the Treatment of Major Depression Complicating Alzheimer's Disease
161 Citations1997Fernando Taragano, Constantine G. Lyketsos +3 more
It is concluded that antidepressant treatment for major depression complicating Alzheimer's disease (AD) is effective, and fluoxetine is better tolerated than amitriptyline.
Journal of Molecular NeuroscienceStatin therapy for Alzheimer’s disease
153 Citations2002Suzana Petanceska, Steven DeRosa +7 more
A study aimed at determining the effects of atorvastatin (LipitorR), a statin with the largest US market share, on brain Aβ deposition in the PSAPP transgenic mouse model of Alzheimer’s amyloidosis, indicates that Lipitor treatment markedly attenuates A β deposition in this animal model.
International Journal of Geriatric PsychiatryA double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia
145 Citations1998Cornelius Katona, Brian Hunter +1 more
To compare the efficacy of paroxetine and imipramine prospectively in patients with coexisting depression and dementia prospectively is compared.
Archives of NeurologyNeuropsychological Patterns and Language Deficits in 20 Consecutive Cases of Autopsy-Confirmed Alzheimer's Disease
136 Citations1993Bruce H. Price, Hakan Gürvıt +4 more
A retrospective chart review of clinical symptoms was done for 20 consecutive patients in whom postmortem examination had revealed senile plaques and neurofibrillary tangles in a distribution consistent with Alzheimer's disease.
Neurobiology of AgingCholine acetyltransferase activity and cognitive domain scores of Alzheimer’s patients☆
124 Citations2000Bruce A. Pappas, Peter J. Bayley +3 more
Results are consistent with current animal research regarding the effect of selective cholinergic lesions on behavior.
New England Journal of MedicineEarly Alzheimer's Disease
116 Citations2003Claudia H. Kawas
A 72-year-old, college-educated woman who comes in for the evaluation of mild memory loss that has been gradually progressing for the past two years has recently made some errors in her checkbook.
Archives of NeurologyOn Drawing Impairment in Alzheimer's Disease
116 Citations1991Andrew Kirk, Andrew Kertesz
Drawings of patients with Alzheimer's disease displayed fewer angles, impaired perspective and spatial relations, simplification, and overall impairment compared with those of the control subjects, representing a combination of the deficits seen following right- and left-hemisphere lesions.
NeurologyConditions associated with Alzheimer's disease at death
114 Citations1986Vijay Chandra, Nadir E. Bharucha +1 more
Differences in the frequency of listing on the death certificates for the following conditions reached statistical significance: infections, trauma, nutritional deficiency, chronic ulcer of skin, foreign body in pharynx, cataract, glaucoma, blindness, deafness, Parkinson's disease, and epilepsy.
European Archives of Psychiatry and Clinical NeuroscienceCross-national comparisons of the occurrence of Alzheimer's and vascular dementias
109 Citations1991Anthony F. Jorm
There is clear evidence that Alzheimer's demintia is more common than vascular dementia in Great Britain and North America and, to a lesser extent, in Scandinavia, and the evidence from Japan generally shows that vascular dementia is moreCommon.
Journal of the American Geriatrics SocietyClock Drawing Test in Very Mild Alzheimer's Disease
108 Citations1998C. Esteban-Santillan, Rungnirand Praditsuwan +2 more
The efficacy of the clock drawing test to predict the presence of very mild Alzheimer's disease (AD) was determined and elements of clock drawing that were most useful in differentiating cognitively intact older adults from those with mild AD were identified.
Alzheimer Disease & Associated DisordersThe Alzheimer's Disease Assessment Scale: Evaluation of Psychometric Properties and Patterns of Cognitive Decline in Multicenter Clinical Trials of Mild to Moderate Alzheimer's Disease
106 Citations2001P. Murali Doraiswamy, Lee Kaiser +2 more
There is a relationship between baseline severity and magnitude of cognitive decline, and in 6-month trials, measurement error makes a substantial contribution to the variance in ADAS-Cog change scores.
Alzheimer Disease & Associated DisordersCombination Therapy of Donepezil and Vitamin E in Alzheimer Disease
79 Citations2003Emily Klatte, Douglas W. Scharre +3 more
The long‐term combination therapy of donepezil and vitamin E appears beneficial for patients with Alzheimer disease and future prospective studies would be needed to compare combination treatment to vitamin E anddonepezil alone.
American Journal of Geriatric PsychiatryAn Open Trial of Valproate for Agitation in Geriatric Neuropsychiatric Disorders
69 Citations1997Anton P. Porsteinsson, Pierre N. Tariot +2 more
This open treatment suggested that valproate reduced agitated behaviors in some patients, and is well tolerated; thus, results warrant a larger, randomized, placebo-controlled study.
Annals of NeurologyHuman apolipoprotein E4 accelerates β‐amyloid deposition in APPsw transgenic mouse brain
67 Citations2001Donald B. Carter, Edwige Dunn +8 more
Mice expressing ApoE4 in combination with APPsw have accelerated Aβ deposition in the brain as assessed by enzyme immunoassay for Aβ40 and Aβ42 extractable in 70% formic acid, by assessment of amyloid plaque formation using thioflavin‐S staining, and by immunohistochemical staining with antibodies specific for A β40 or A β42 and the 4G8 monoclonal or 162 polyclonal antibody.
Journal of Molecular NeuroscienceDevelopment of a new treatment for alzheimer’s disease and parkinson’s disease using anti-aggregatory β-synuclein-derived peptides
48 Citations2002Manfred Windisch, Birgit Hutter‐Paier +4 more
Journal of Geriatric Psychiatry and NeurologyComplementary and Alternative Medicines for Alzheimer's Disease
21 Citations1998Brian R. Ott, Norma J. Owens
This review brings to focus the scientific evidence presently available regarding agents biologically active in modulating the disease as well as producing side effects and interactions with accepted pharmaceuticals.
PsychogeriatricsHealth Economical Aspects of Alzheimer Disease and its Treatment
21 Citations2001Anders Wimo, Bengt Winblad
In particular, aspects of quality of life among patients and caregivers, long term treatment effects and informal care should be the focus for methodological development.
…